13631 Progress Boulevard
About AxoGen, Inc.
138 articles with AxoGen, Inc.
Axogen Announces Publication of the 100th Peer-Reviewed Clinical Paper Featuring its Product Portfolio for Peripheral Nerve Repair
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced publication of the 100th peer-reviewed paper featuring results from clinical studies involving its product portfolio.
Axogen Shareholder Alert: Claimsfiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Axogen, Inc. - Axgn
ClaimsFiler reminds investors that they have until March 11, 2019 to file lead plaintiff applications in a securities class action lawsuit against AxoGen, Inc., if they purchased the Company's securities in connection with its November 2017 or May 2018 secondary public offering or between August 7, 2017 and December 18, 2018, inclusive.
Report Shows Life Science Companies Continue to Be a Favorite Target of Securities Fraud Class Ac...
2/8/2019Despite a decline over the past year of class-action lawsuits, life science companies remain a popular target for securities fraud litigation.
RM LAW, P.C. announces that a class action lawsuit has been filed on behalf of all persons or entities that purchased AxoGen, Inc.
The law firm of Kessler Topaz Meltzer & Check, LLP alerts investors that a securities fraud class action lawsuit has been filed against AxoGen, Inc. (Nasdaq: AXGN) ("AxoGen") on behalf of purchasers of AxoGen securities
AxoGen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that the RECON® Study supporting its Biologic License Application (BLA) Submission for Avance® Nerve Graft has reached its current enrollment milestone of 170 subjects.
AXOGEN INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates AxoGen, Inc. for Possible Securities Fraud - AXGN
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into AxoGen, Inc. (NasdaqCM: AXGN).
As a female chief executive officer in the healthcare industry Karen Zaderej often stands out in a male-dominated industry.
AxoGen to Report Fourth Quarter and Full-Year 2017 Financial Results and Host Conference Call on February 28, 2018
AxoGen management will host an investment-community conference call and webcast following the release at 4:30 p.m. ET to discuss the financial results and provide a corporate update.
Fourth quarter revenue is expected to be at least $16.5 million, up 45% compared to the fourth quarter of 2016 revenue of $11.4 million.
Barring a huge meltdown, the S&P 500 will once again have a double-digit year of gains, and most investors should be looking at their 401(k)s and other accounts with some added holiday cheer.
The total net proceeds from the offering for AxoGen are estimated to be approximately $15.4 million
Additionally, the company will announce its newest application in breast reconstruction neurotization and outline its continued effort to evaluate expansions of the company’s portfolio of products in the surgical management of pain.
The offering consists of 700,000 shares being sold by AxoGen and 1,000,000 shares being sold by EW Healthcare Partners L.P.
AxoGen executives and surgeon thought leaders will discuss the company’s comprehensive platform for peripheral nerve repair and the emerging nerve repair market.
AxoGen management will host an investment-community conference call and webcast following the release at 4:30 p.m. ET.
AxoGen To Report Second Quarter 2017 Financial Results And Host Conference Call On Wednesday, August 2, 2017